Korean Regulatory Post Marketing Surveillance for Somavert

KOREAN POST-MARKETING SURVEILLANCE FOR SOMAVERT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05131100

Enrollment

Registered

2021-11-23

Start date

2022-07-13

Completion date

2025-11-10

Last updated

2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Keywords

acromegaly, Somavert, Post-Marketing Surveillance

Brief summary

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Interventions

DRUGSomavert

As provided in real world practice

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.

Exclusion criteria

Patients who are contraindicated for Somavert

Design outcomes

Primary

Measure	Time frame
Number of participants who experience adverse events	Baseline through 28 days after last dose (approximately 52 weeks)

Secondary

Measure	Time frame
Number of participants who experience Clinical Improvement as assessed by investigator	Baseline through approximately 52 weeks

Countries

South Korea

Contacts

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026